# Phase 2 neuroblastoma trials recruiting: 22 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 22 trials in phase 2 for neuroblastoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 neuroblastoma trials: 22 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/neuroblastoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 22
- Recruiting or not yet: 22
- Read on: November 19, 2026

## Trials

The 22 newest of 22, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07932808 | Naxitamab Enabled Transplant-Free Study in High-Risk Neuroblastoma | Sponsor not shown (see the record) | Phase 2 | Recruiting | Neuroblastoma | 101 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07932808) |
| June 9, 2026 | NCT07635056 | Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma | Children's Hospital Medical Center, Cincinnati | Phase 2 | Recruiting | Neuroblastoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07635056) |
| April 17, 2026 | NCT07537400 | Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group... | Shaare Zedek Medical Center | Phase 2 | Recruiting | High-Risk Neuroblastoma | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07537400) |
| January 6, 2026 | NCT07318831 | Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Recruiting | Neuroblastoma (NB), Neuroblastoma in Children | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07318831) |
| December 3, 2025 | NCT07261241 | NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab | New Approaches to Neuroblastoma Therapy Consortium | Phase 2 | Not yet recruiting | Neuroblastoma | 118 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07261241) |
| August 8, 2025 | NCT07111117 | Comparison of 18F Labeled Analog of MIBG (18F-MFBG) PET/CT and 123I-MIBG SPECT in Pediatric Patients With Neuroblastoma. | Institut Curie | Phase 2 | Not yet recruiting | Neuroblastoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07111117) |
| April 18, 2025 | NCT06933394 | Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 | Recruiting | Neuroblastoma | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06933394) |
| August 7, 2024 | NCT06540963 | Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma | Sponsor not shown (see the record) | Phase 2 | Recruiting | Neuroblastoma | 98 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06540963) |
| July 30, 2024 | NCT06528496 | N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06528496) |
| June 10, 2024 | NCT06450041 | NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial | New Approaches to Neuroblastoma Therapy Consortium | Phase 2 | Recruiting | Neuroblastoma | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06450041) |
| September 28, 2023 | NCT06057948 | A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Neuroblastoma, High-risk Neuroblastoma, Metastatic Neuroblastoma | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06057948) |
| August 28, 2023 | NCT06013618 | Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma | Sun Yat-Sen University Cancer Center | Phase 2 | Recruiting | Neuroblastoma | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06013618) |
| August 5, 2022 | NCT05489887 | Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma | Sponsor not shown (see the record) | Phase 2 | Recruiting | Neuroblastoma | 93 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05489887) |
| March 31, 2022 | NCT05303727 | Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 | Not yet recruiting | Neuroblastoma | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05303727) |
| November 26, 2021 | NCT05135975 | A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors | Nationwide Children's Hospital | Phase 2 | Recruiting | Neuroblastoma, Sarcoma | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05135975) |
| June 23, 2021 | NCT04936529 | A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Neuroblastoma | 286 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04936529) |
| May 27, 2021 | NCT04903899 | 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma | Sponsor not shown (see the record) | Phase 2 | Recruiting | Neuroblastoma Recurrent, Neuroblastoma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04903899) |
| September 22, 2020 | NCT04559217 | 68Ga-DOTATATE Neuroblastoma Imaging Pilot | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | Phase 2 | Recruiting | Neuroblastoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04559217) |
| November 16, 2015 | NCT02605421 | Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma | Masonic Cancer Center, University of Minnesota | Phase 2 | Recruiting | Neuroblastoma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02605421) |
| September 24, 2015 | NCT02559778 | Pediatric Precision Laboratory Advanced Neuroblastoma Therapy | Sponsor not shown (see the record) | Phase 2 | Recruiting | Neuroblastoma | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02559778) |
| March 5, 2013 | NCT01804634 | Reduced Intensity Haploidentical BMT for High Risk Solid Tumors | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | Recruiting | Refractory and/or Relapsed Metastatic Solid Tumors | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01804634) |
| April 6, 2005 | NCT00107289 | Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant... | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Neuroblastoma, Pheochromocytoma | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00107289) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Memorial Sloan Kettering Cancer Center | 4 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2 |
| New Approaches to Neuroblastoma Therapy Consortium | 2 |
| Masonic Cancer Center, University of Minnesota | 1 |
| Sun Yat-Sen University Cancer Center | 1 |
| Institut Curie | 1 |
| Centre de recherche du Centre hospitalier universitaire de Sherbrooke | 1 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 1 |
| Children's Hospital Medical Center, Cincinnati | 1 |
| Tianjin Medical University Cancer Institute and Hospital | 1 |
| Shaare Zedek Medical Center | 1 |
| Nationwide Children's Hospital | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 14 |
| China | 4 |
| Canada | 3 |
| Spain | 2 |
| France | 1 |
| Israel | 1 |
| Denmark | 1 |
| Lithuania | 1 |
| Netherlands | 1 |
| Norway | 1 |
| Sweden | 1 |
| United Kingdom | 1 |
| Brazil | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Filipino restaurants in the United States](https://specstream.ai/data/businesses/filipino-restaurants/united-states)
- [Locksmiths in the United States](https://specstream.ai/data/businesses/locksmiths/united-states)
- [Public relations firms in the United States](https://specstream.ai/data/businesses/public-relations-firms/united-states)
- [Vietnamese restaurants in the United States](https://specstream.ai/data/businesses/vietnamese-restaurants/united-states)
- [British restaurants in the United States](https://specstream.ai/data/businesses/british-restaurants/united-states)
- [Environmental testing companies in the United States](https://specstream.ai/data/businesses/environmental-testing-companies/united-states)
